Beacon Securities initiated coverage of Profound Medical (TSXV:PRN) with a “buy” rating and 12-month price target of $3.10. The stock closed at $1 on Feb. 28. “We believe Profound Medical is a company who is building...

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $3.50 from $2.50 after the company presented Phase 1/2 data suggesting its NanoFlu vaccine has the potential to be the most potent product for...

Roth Capital Partners launched coverage of Acer Therapeutics (NASDAQ:ACER) with a “buy” rating and price target of $70. The stock closed at $17.28 on Feb. 23. Acer’s focuses on vascular Ehlers-Danlos Syndromes (vEDS), a...

Roth Capital Partners launched coverage of ArQule (NASDAQ:ARQL) with a “buy” rating and $5 price target. The stock closed at $1.67 on Feb. 21. “We believe that the value-driving components of the pipeline have been in...

Stifel upgraded Momenta Pharmaceuticals (NASDAQ:MNTA) to “buy” from “hold” and raised its price target to $21 from $18. The stock closed at $16.35 on Feb. 21. “As part of our stock call, we acknowledge two opposing...

Roth Capital Partners initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $1.69 on Feb. 20. The company’s value driver, Sollpura, is an oral...

Analysts for Ladenburg Thalmann and Roth Capital Partners initiated coverage of Eyenovia (NASDAQ:EYEN) with “buy” ratings and price targets of $35 and $20, respectively. The stock closed at $9 on Feb. 16. Eyenovia...

Leerink launched coverage of resTORbio (NASDAQ:TORC) with an “outperform” rating and $36 price target. The stock closed at $18.76 on Feb. 16. “Our rating and valuation are based on our sales forecast for lead asset...

Leerink initiated coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating and $36 price target. The stock closed at $24.93 on Feb. 16. “We are encouraged by the preclinical data generated for...

William Blair launched coverage of Acer Therapeutics (NASDAQ:ACER) with an “outperform” rating and fair value estimate of $47. The stock closed at $17 on Feb. 15. Acer is developing two late-stage clinical...

Maxim Group slashed its price target for Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC) to €6 from €12, citing the company’s data through mid-2019. The stock closed at €2.75 on Feb. 14...

Maxim Group downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “hold” from “buy” and removed its previous $14 price target after the company announced that top-line results from the ARRIVE trial...

Maxim Group slashed its price target to Anavex Life Sciences (NASDAQ:AVXL) to $5 from $14, saying the company’s definitive proof-of-concept studies will take time and money. The stock closed at $2.54 on Feb. 13...

Ladenburg Thalmann more than tripled its price target for Catalyst Biosciences (NASDAQ:CBIO) to $47 from $14.25 after the company reported compelling hemophilia B data at a medical conference in Europe. The stock closed...

Roth Capital Partners launched coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $20 price target. The stock closed at $5.04 on Feb. 7. Conatus is a leader in the pan-caspase...

RBC Capital Markets initiated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with an “outperform, speculative risk” and price target of $9. The stock closed at $5.23 on Feb. 7. The company’s drug...

William Blair launched coverage of AxoGen (NASDAQ:AXGN) with an “outperform” rating. The stock closed at $26.65 on Feb. 2. AxoGen is a global leader in the peripheral nerve repair and regeneration industry, and sells a...

Roth Capital Partners initiated coverage of Epizyme (NASDAQ:EPZM) with a “buy” rating and $24 price target. The stock closed at $16.15 on Jan. 31. Analyst Jotin Marango writes that during the past five years in the...

Aegis Capital initiated coverage of IntelGenx (OTCQX:IGXT) with a “buy” rating and $3 price target. The stock closed at 88 cents on Jan. 26. IntelGenx has more than a dozen generic oral film and oral-dissolving tablet...

Ladenburg Thalmann initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $25.50 price target. The stock closed at $12.07 on Jan. 26. Zynerba is developing two clinical-stage synthetic...

Stifel launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with a “buy” rating and a $32 target price. The stock closed at $19.23 on Jan. 26. Protagonist is leveraging its proprietary peptide technology platform...